Proposed mechanisms for bariatric surgery-induced improvement and resolution of clinical manifestations of type II diabetes by Ionson, Annaliese Claire
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Proposed mechanisms for bariatric
surgery-induced improvement and
resolution of clinical manifestations
of type II diabetes
https://hdl.handle.net/2144/26731
Boston University
  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
PROPOSED MECHANISMS FOR BARIATRIC SURGERY-INDUCED 
IMPROVEMENT AND RESOLUTION OF CLINICAL MANIFESTATIONS OF 
TYPE II DIABETES  
 
 
 
by 
 
 
 
 
ANNALIESE IONSON 
 
B.A., Princeton University, 2015 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 ANNALIESE IONSON 
 All rights reserved
  
 
Approved by 
 
 
 
 
First Reader   
 Maryann Macneil, M.A.  
 Instructor of Anatomy and Neurobiology 
 
 
Second Reader   
 Caroline Apovian, M.D.  
 Professor of Medicine 
 
 
 
  iv 
ACKNOWLEDGMENTS 
A special thank you to my readers, Ms. M. Macneil and Dr. C. Apovian, for providing 
time and feedback to help complete and enhance this work. To Ms. M. Agosto, thank you 
for your assistance navigating the administrative side of this project. Lastly, I would like 
to acknowledge and thank Dr. S. Wasan for first sparking my interest in the effects of 
bariatric surgery on diabetes. 
 
  
  v 
PROPOSED MECHANISMS FOR BARIATRIC SURGERY-INDUCED 
IMPROVEMENT AND RESOLUTION OF CLINICAL MANIFESTATIONS OF 
TYPE II DIABETES  
ANNALIESE IONSON 
 
ABSTRACT 
At the 2nd Diabetes Surgical Summit in 2015, the world’s leading researchers and 
professionals in the field of diabetes, surgery, and public health gathered to develop new 
surgical treatment guidelines for diabetes. This summit led to the recommendation of 
bariatric surgery as an official treatment for type II diabetes, outlining that the surgery be 
considered for diabetic patients with a Body Mass Index (BMI) of 30, a much lower 
threshold BMI than that of typical bariatric surgery patients. Despite incontrovertible 
evidence that bariatric surgery can reverse the progression of diabetes and even cause 
remission, the physiological mechanisms chiefly responsible for these effects remain 
controversial.   
 
Peer-reviewed published literature was collected to examine the evidence for mechanisms 
responsible for metabolic improvements following bariatric surgery, especially Roux-en-
Y gastric bypass. This review considered the effects of calorie restriction, appetite 
modulators, incretins, intestinal adaptations, adipose tissue, gut microbiota, bile acid 
circulation and composition, and psychosocial and behavioral changes on surgery-
induced metabolic improvements and sustained type II diabetes remission. Clinical 
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considerations, such as the surgical risks and improved indicators for bariatric surgery 
were also explored to contextualize the physiological mechanisms under study. 
  
The “hind gut hypothesis” emerged as an important overarching mechanism potentially 
responsible for many of the observed improvements. The more rapid delivery of food to 
the distal intestine, as well as the delayed mixing of pancreatic, gastric and bile secretions 
with food, likely contributes to increased nutrient-stimulation of enteroendocrine cells 
and greater binding of bile acids with their receptors, farnesoid X receptor and TGR5. 
These changes in food and secretion delivery also appear to positively affect the gut 
microbiota to support a non-obese microbiota profile. Calorie restriction may be 
responsible for the early effects of bariatric surgery, including not just a reduction in fat 
mass but also epigenetic changes to induce β-cell proliferation and increased insulin 
secretion. However, long-term benefits of bariatric surgery appear to be more closely 
correlated to enteroendocrine changes, including the surgery-induced changes to levels of 
appetite modulators that, unlike pure calorie restriction, promote feelings of satiation and 
reduce rates of diet failure and weight regain. 
 
Fat distribution and adipocyte function are also important contributors to both the 
pathophysiology of obesity-related diabetes and improvements following bariatric 
surgery. While reductions in BMI and subcutaneous adipose tissue area were not 
correlated to diabetes remission, reductions in visceral adipose tissue area and enhanced 
adiponectin secretions were both independent factors associated with diabetes remission. 
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The important role of adipocytes as endocrine organs has emerged as an important field 
of inquiry. Adipokines, adipocyte hormones, may either promote a pro-inflammatory 
profile or an anti-inflammatory profile, impacting the development of obesity-related 
diabetes or diabetes remission, respectively.  
 
The findings of this review support the 2nd Diabetes Surgical Summit’s recommendations 
of proactive bariatric surgery as a treatment for diabetes. The risks of complications and 
mortality following bariatric surgery are low, whereas the long-term survival after 
bariatric surgery is improved relative to non-surgical, matched controls. Single-
nucleotide polymorphisms associated with obesity and diabetes may serve as early 
indicators for surgery, and inform both surgical method and follow-up protocols.  
 
Despite the benefits of bariatric surgery, only a small number of eligible candidates 
undergo treatment. In the United States, barriers such as physician and patient 
perceptions and cost may limit access to surgery. In places that experience a health 
workforce shortage, there may be no health care professionals or facilities available to 
perform bariatric surgery. Therefore, while the surgery amazingly causes diabetes 
remission, one of its greatest benefits may be to continue to inform the mechanisms 
responsible for metabolic improvements toward developing new pharmacological 
treatments. In the future, less invasive drug treatments that seek to replicate the effects of 
bariatric surgery may be more successful in tackling the global obesity and diabetes 
crisis.   
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INTRODUCTION 
In 2015, an estimated 196,000 bariatric surgeries were performed in the United States 
(American Society for Metabolic and Bariatric Surgery, 2016). This number represents 
an increase of approximately 38,000 surgeries since 2011, reflecting the climbing rate of 
obesity in the United States and worldwide. Trend analyses of the obesity rate in the US 
each year from 2005 – 2012 demonstrate a significant positive linear trend, with the 
2013-2014 age-adjusted obesity rate of over one third the national population (37.7%) 
(Flegal et al., 2016). Bariatric surgery may be indicated for adults between the ages of 18 
and 60 years with: 1) Body Mass Index (BMI)1 ≥ 40 kg/m2 (class III obesity); or 2) BMI 
≥ 35 kg/m2  (class II obesity) with serious co-morbidities that may improve from weight 
loss, such as type II diabetes2, cardiovascular disease (CVD), sleep apnea, and severe 
joint disease (Lucchese et al., 2015; 
The National Institute of Diabetes and 
Digestive and Kidney Diseases, 2016).  
 
Obesity is an independent risk factor 
for diabetes, with 55% of the burden of 
diabetes attributed directly to obesity, 
as defined by BMI (Sassi et al., 2009). 
                                                        
1 BMI is measured by dividing a person’s weight in kilograms by the square of his or her height in meters. 
While it does not measure body fat directly, it is moderately correlated with body fat and is the most 
common and inexpensive method for assigning weight categories (Table 1) (CDC, 2016). 
2 Any reference to diabetes throughout this paper will refer to type II diabetes, unless otherwise specified. 
Table 1. Adult Body Mass Index (BMI) 
BMI Class 
<18.5 Underweight 
18.5 - <25 Normal 
25.0 - <30 Overweight 
30 - <35 Class I Obesity 
35 - <40 Class II Obesity 
40+ Class III Obesity 
Source: (CDC, 2016) 
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In the United States, diabetes affects over 25 million people. It is the leading cause of 
kidney failure, non-traumatic lower limb amputations, new cases of blindness among 
adults, and one of the main causes of CVD and stroke. Overall, it is the seventh leading 
cause of death in the United States and the sixth leading cause of death in the world 
(Centers for Disease Control and Prevention, 2011; WHO, 2017). In 2007, diabetes-
related health care spending in the U.S. totaled over $174 billion dollars, and these costs 
are expected to increase with rising diabetes prevalence (Boyle et al., 2010). National 
diabetes prevalence is projected to more than double from current levels of around 9% to 
up to 28% by 2050 (Boyle et al., 2010). Moreover, children under the age of 18 years are 
increasingly making up a larger portion of the total type II diabetes prevalence. 
Historically, most cases of diabetes in children are type I: in the mid-1990’s, only 1-2% 
of children with diabetes had type II. More recently, studies report 25-45% of all children 
diagnosed with diabetes as having type II (Pulgaron and Delamater, 2014). These 
children have a heightened risk of complications, especially vascular and psychological 
morbidities, and require an expensive expansion of diabetes healthcare delivery (Wilmot 
and Idris, 2014). 
 
Given the high burden of obesity and diabetes, there is an urgent need to improve 
treatment options for patients. Diabetes has largely been considered a chronic, 
progressive, and irreversible condition. However, bariatric surgery has the potential to 
improve or resolve diabetes’ clinical manifestations.  
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Bariatric Surgery 
Twenty-two years ago, Pories et al. (1995) published their ground-breaking article, “Who 
would have thought it? An operation proves to be the most effective therapy for adult-
onset diabetes”. The bold claim of the title alone has stood the test of time and intensive 
inquiry. A systematic review and meta-analysis by Buchwald et al. (2004) of 621 studies 
found 78.1% of diabetic patients had complete diabetes remission, and 86.6% of patients 
had remission or improvement at 2 or more years following bariatric surgery. While 
diabetes remission rates following surgery may decrease over time, Sjöström et al. (2014) 
reported nearly one-third of bariatric surgery patients maintained diabetes remission at 15 
years post-surgery. Increased weight loss and reduced weight regain have been correlated 
with diabetes remission in some studies (Brethauer et al., 2006). The American Diabetes 
Association (ADA) defines “remission” as having normal ranges of fasting blood glucose 
(less than 100 mg/dL) and HbA1c levels (less than 5.7 percent) without taking diabetes 
medication, irrespective of BMI (ADA, 2017). 
  
Bariatric surgery, particularly Roux-en-Y Gastric Bypass (RYGB), achieves significant 
and rapid reductions in fasting glucose, insulin, triglycerides (TGs), total cholesterol and 
inflammatory biomarkers. Hepatic insulin sensitivity improves in as few as three days 
after surgery (Shankar et al., 2017). The normalization of glucose homeostasis and 
insulin sensitivity observed after bariatric surgery is significant, durable, and rarely 
observed with any other traditional treatments, such drug therapies. Evidence 
demonstrating the beneficial therapeutic effects of bariatric surgery led the 2nd Diabetes 
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Surgical Summit to update treatment guidelines: bariatric surgery is now recommended to 
treat diabetic patients with class II or III obesity, and should be considered for patients 
with a BMI between 30.0 – 34.9 kg/m2 and poorly controlled hyperglycemia (Rubino et 
al., 2016).  
 
Bariatric surgery procedures can be divided into two large subcategories: restrictive or 
malabsorptive3. Restrictive methods reduce the size and capacity of the stomach to limit 
food intake and slow gastric emptying, promoting and prolonging a feeling of satiation. 
This includes laparoscopic adjustable gastric banding (LAGB) (Knop and Taylor, 2013). 
Restrictive methods align with hypotheses that support negative calorie balance and 
decreased hepatic and pancreatic fat as the main mechanisms responsible for post-
operative normalization of glucose metabolism and insulin sensitivity (See Calorie 
Restriction and Adipose Tissue Sections).  
 
Malabsorptive methods reduce the size of the stomach and divert food’s passage directly 
to the distal intestine, bypassing the proximal intestine where most absorption occurs and 
resulting in more rapid delivery to the distal intestine. These methods include the most 
common form of bariatric surgery, the RYGB (Figure 1). Malabsorptive methods include 
not only a calorie restriction model, but also align with hypotheses that support 
enteroendocrine changes that impact the enteroinsular and adipoinsular axes and appetite 
regulation (Knop and Taylor, 2013). Diabetes remission rates and metabolic 
                                                        
3 See Appendix A for a description of specific bariatric surgery procedures.  
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improvements are better with malabsorptive methods than with purely restrictive ones. 
The highest rate of remission is achieved following biliopancreatic diversion (BPD), 
though this is performed less frequently due to higher rates of complication and severe 
nutrient deficiencies (Nandagopal et al., 2010). RYGB is considered the “gold standard” 
of bariatric surgery due to its high rates of diabetes remission and weight loss and low 
rates of complication (Singh et al., 2015).  
 
The Debate 
Despite irrefutable evidence that bariatric surgery improves or resolves diabetes, the 
physiological mechanisms directly responsible for these improvements remain 
controversial. The effects of weight loss on insulin sensitivity are well documented 
Figure 1. Roux-en-Y Gastric Bypass: The stomach is divided to create a 
small upper pouch for the new stomach. The small intestine is divided and 
the distal end of the small intestine is anastomosed to the small pouch 
stomach. The proximal segment of the small intestine is anastomosed to a 
lower segment of the distal small intestine so that gastric and pancreatic 
secretions mix with food in the distal jejunum or ileum. Taken from 
Blausen.com staff, 2014. 
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(Goodpaster et al., 1999; Schenk et al., 2009). However, the nearly immediate glucose 
lowering effects in the days following surgery suggest other mechanisms beyond weight 
loss. A return to normal glucose levels from insulin-treated hyperglycemia has been 
observed as early as within seven days of BPD (Knop and Taylor, 2013).  
 
The foregut and hindgut hypotheses drive the current thinking with regard to the 
superiority of malabsorptive methods (RYGB, BPD), over purely restrictive methods 
(LAGB). Traditionally, the hindgut hypothesis postulates that increased nutrient 
stimulation of the distal intestine through the more rapid delivery of food contents 
increases the levels of incretins, enteroendocrine hormones that stimulate insulin 
secretion and suppress glucagon, improving glucose metabolism. Meanwhile, the foregut 
hypothesis postulates the existence of anti-incretins produced mainly by the proximal 
intestine that counteract and balance the effects of incretins. Decreased nutrient 
stimulation in the bypassed proximal intestine would not only raise incretin levels, but 
also decrease levels of the anti-incretin duodenal factor. Thus, research that supports the 
foregut and hindgut hypotheses argues early metabolic improvements, independent of 
weight loss, are specifically due to intestinal reconfiguration (Mingrone and Castagneto-
Gissey, 2009).  
 
Another school of thought argues that the early and long-term improvements in 
metabolism of both restrictive measures and malabsorptive measures are achieved via 
calorie restriction and weight loss. In line with this thinking, the supposed superiority of 
malabsorptive methods is not due to intestinal reconfiguration, but more severe calorie 
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restriction and enhanced weight loss through malabsorption. There is evidence to support 
this view. Klein et al. (2012) conducted a prospective trial to determine whether the 
RYGB intestinal reconfiguration without gastric exclusion (reduced stomach size) 
resulted in the same therapeutic effects in patients with diabetes. While there were 
improvements in HbA1c levels and greater insulin synthesis and excretion in response to 
glucose tests, β-cell function remained 70% lower than matched (BMI, race, age, sex) 
controls with normal glucose tolerance (Klein et al., 2012). Klein et al. (2012) concluded 
that intestinal reconfiguration had moderate therapeutic effects in the first year following 
surgery, and that marked weight loss or gastric exclusion may be more significant 
contributors.  
 
Another study found that though the postprandial enteroendocrine profiles following 
RYGB and LAGB are markedly different, they both resulted in the same anti-
inflammatory adipokine profiles, oral glucose tolerance, insulin sensitivity and beta cell 
function (Bradley et al., 2012). Moreover, when matched on weight loss (~20%), RYGB 
and sleeve gastrectomy (SG) surgeries achieved similar improvements in postprandial 
insulin action and glucose tolerance in non-diabetic, insulin-resistant patients, six months 
after surgery (Bradley et al., 2014). These finding support that weight loss and calorie 
restriction, not intestinal reconfiguration, are chiefly responsible for metabolic 
improvements.  
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However, theories that support either a purely foregut/hindgut view or calorie 
restriction/weight loss view may fail to appreciate the complexity of metabolic changes 
following bariatric surgery. Investigation of the mechanisms responsible for metabolic 
improvements (i.e. insulin sensitivity, glucose tolerance, reduced appetite) reveals the 
potential role of many factors, including intestinal and neuronal adaptations, bile acid 
circulation, adipocyte function, and epigenetic changes. Moreover, there is a dearth of 
long-term (>1-2 years), prospective studies using large patient samples. For instance, the 
study by Bradley et al. (2014) drew conclusions on the effects of RYGB and LAGB after 
merely six months of observation of a total of 14 patients. Therefore, with regard to the 
responsible mechanisms of surgery-induced metabolic improvements, there remains 
much debate and uncertainty. A greater understanding of the physiological mechanisms 
driving metabolic changes induced by bariatric surgery may improve treatment guidelines 
and unveil potential drug targets and therapeutic agents for diabetes treatment.  
Specific Aims 
Specific aims of the following thesis include:  
 
1. Comprehensive review of literature to identify proposed mechanisms for both 
the pathophysiology of metabolic dysfunction and the resolution or 
improvement of clinical manifestations of type II diabetes following bariatric 
surgery, particularly RYGB.    
2. Weigh the risks and benefits of bariatric surgery and identify methods to 
improve outcomes. 
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3. Conclusion on the mechanisms chiefly responsible for remission of type II 
diabetes following bariatric surgery, and future directions in treatment and 
research.
 10 
CALORIE RESTRICTION 
Bariatric surgery requires severe calorie restriction post-operatively. In the first two 
months following surgery, daily caloric intake should aim to be between 300 – 600 
calories per day, and come entirely from liquefied food (“Dietary Guidelines After 
Bariatric Surgery,” 2017). Some researchers believe that this calorie restriction is chiefly 
responsible for surgery-induced weight loss and improvements to glucose homeostasis, 
insulin sensitivity and β-cell function, while other mechanisms, such as the “incretin 
effect” (see Incretins Section) are concerned with “fine-tuning, not primary control, of 
metabolism” (Knop and Taylor, 2013). 
 
There is evidence to support this view. Jackness et al. (2013) conducted a study to 
compare RYGB and very-low-calorie diet (VLCD) interventions’ effects on weight loss, 
insulin sensitivity, acute insulin secretion following an intravenous (IV) glucose 
administration (to control for the nutrient-stimulated release of incretins observed in oral 
glucose tests), and β-cell function. The subjects were mean-matched for BMI, HbA1c4, 
and diabetes duration. After 21 days, both groups had similar improvements in insulin 
sensitivity and β-cell function.  
 
                                                        
4 HbA1c is usually reported as a percentage and measure of proportion of glycosylated hemoglobin. It is a 
good indicator of average blood sugar levels over an extended period. Normal levels are below 6%, 
diabetes is defined as over 6.5%. Decreases in HbA1c levels protect against microvascular complications 
(i.e. neuropathy, retinopathy, nephropathy) (Diabetes.co.uk, 2017a). 
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Proposed chief mechanism responsible for the improvements in insulin sensitivity and β-
cell function with calorie restriction alone have focused on reductions in liver and 
pancreatic fat, in line with the “twin-cycle hypothesis” (see Adipose Tissue section) 
(Knop and Taylor, 2013). However, new evidence suggests epigenetic adaptations to 
nutrient-stress. Cheng et al. (2017) used a 4-day fasting mimicking diet (FMD) that 
caused changes in levels of specific growth factors, glucose, and ketone bodies similar to 
those caused by water-only fasting.  
In short, Cheng et al. (2017) found that FMD-induced β-cell regeneration may occur via a 
de-differentiation of pancreatic cells toward pluripotency at the end of 4-day FMD, 
followed by a re-differentiation to pancreatic β-cell lineage during the re-feeding period. 
In rodent models, six to eight cycles of FMD and re-feeding restored normal β-cell mass 
and insulin secretion function following an initial high-dose streptozotocin (STZ) 
injection to induce type I diabetes (greater than 70% β-cell loss; Figure 2 & 3). Ex-vivo 
treatments on human islet cells from both healthy and type I diabetic patients treated with 
Figure 2. FMD cycles promote β-cell regeneration in pancreatic islets following STZ treatment:  
Micrographs of immunostained pancreatic islets for insulin (red), glucagon (green) and DAPI (4',6-
diamidino-2-phenylindole, blue; used to stain for DNA-content to identify cell nuclei). Untreated 
(CTRL): normal, control subject islet. STZ BL (d5): islet 5 days after STZ treatment. STZ (d50): 50 
days after STZ treatment. STZ + FMD (d50): 50 days after STZ treatment followed by cycles of FMD 
and refeeding. Notice the difference in number of insulin-secreting β-cells (red) between STZ and STZ 
+ FMD treated mice at d50. Scale bar, 50 mm. (Taken from Cheng et al., 2017) 
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serum from FMD-treated individuals induced insulin secretion (Cheng et al., 2017). 
Moreover, investigations of lineage-reprogramming markers in treated human islet cells 
share common results with rodent models, indicating an islet cell re-programming to the 
β-cell lineage. These findings suggest that calorie restriction and diet-content may alter 
gene expression profiles from one that suppresses the generation of β-cells to one that 
regenerates β-cell function. Harnessing this reprogramming effect could have future 
therapeutic potential for both type I and type II diabetes.  
 
 
While the discovery of diet-induced epigenetic changes support the significance of 
calorie restriction to the observed effects of bariatric surgery, the compensatory changes 
in appetite modulators (see Appetite modulator section) limit the long-term success of 
calorie restriction alone. The Swedish Obese Subjects study – a long-term, prospective, 
Figure 3. FMD cycles reverse STZ-induced β-cell depletion and restore glucose homeostasis: 
The graph on the left shows significant increases in the proportion of insulin-producing β cells at 
both 30 days (d30) and 50 days (d50) after STZ-treatment. The graph on the right shows 
improved glucose tolerance following an intra-peritoneal glucose tolerance test (IPGTT), 
indicative of effective glucose-stimulated insulin secretion and sensitivity. *p < 0.05, **p < 0.01, 
*** p < 0.005, one-way ANOVA. Ctrl, STZ-untreated control; STZ BL, baseline level of STZ-
treated mice at day 5. (Taken from Cheng et al., 2017) 
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controlled trial – matched bariatric surgery patients to non-surgical controls. The non-
surgical controls underwent conventional treatments, which ranged from sophisticated 
lifestyle interventions to no treatment at all. Patients follow up occurred at regular 
intervals for up to 20 years. Sustained weight loss following RYGB was far superior than 
both the control and banding techniques (including LAGB), with only 3% weight loss 
among the controls compared to 27% weight loss among RYGB patients at 15 years 
follow-up (Figure 4) (Sjöström, 2013).  
 
Figure 4. Mean percentage weight change amongst patients in control and 
bariatric surgery groups over a 20-year follow-up period:  Control, non-
surgical group with either lifestyle interventions or no treatment. Banding 
techniques included banding (LAGB) and vertical banded gastroplasty (VBG). 
GBP, gastric bypass (RYGB). Error bars represent 95% confidence intervals. 
Taken from Sjöström, 2013.  
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Diabetes remission rates are similar across different methods of bariatric surgery (RYGB, 
sleeve gastrectomy and LAGB) in the short term (≤1 year). However, at two or more 
years follow-up, diabetes remission for LAGB and RYGB is 58.3% and 70.9%, 
respectively (Buchwald et al., 2009). The superiority of RYGB in the long term suggests 
that calorie restriction may only be responsible for early, short-term effects, whereas 
other intestinal factors (incretins, bile acids, malabsorption, intestinal adaptations) may be 
responsible for the long-term durability of weight loss and diabetes remission (Figure 5) 
(Vella, 2013).  
 
  
Figure 5. Time course of diabetes remission rates following 
different methods of bariatric surgery: While all methods 
share comparable rates of diabetes remission in the early phase 
(0 – 24 weeks), the superiority of RYGB in achieving diabetes 
remission emerges over the late phase (> 24 weeks). RYGB, 
Roux-en-Y gastric bypass; SG, sleeve gastrectomy; AGB, 
adjustable gastric banding. Putative representation. Taken 
from Vella, 2013) 
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APPETITE MODULATORS 
A number of modulators and signals tightly control appetite, feelings of hunger or 
satiation. There are two main pathways regulating appetite: orexigenic for appetite 
stimulation, and anorexigenic for appetite inhibition. These pathways begin with 
receptors at the arcuate nucleus that bind appetite modulators and then signal to higher 
order neurons in the paraventricular nucleus (Figure 6). Anorexigenic appetite 
modulators include GLP-1, leptin, insulin, and peptide YY (PYY). The only orexigenic 
appetite modulator is ghrelin (Rao, 2012).  
 
 
Orexigenic effects: 
↑ Appetite  
↓ Energy expenditure 
Anorexigenic effects: 
↓ Appetite  
↑ Energy expenditure 
Brain stem and hypothalamus (i.e. arcuate 
nucleus) receive inputs and transmit 
signals to higher order neurons involved in 
award, motivation, appetite and feeding 
Ghrelin 
(Stomach) 
CCK 
(Intestine) 
Insulin 
(Pancreas) 
Leptin 
(Adipose) 
PYY 
(Intestine) 
GLP-1 
(Intestine) 
Figure 6. Simplified Model of Appetite Modulation Signaling 
 16 
The compensatory effects of appetite modulators limit the success of calorie restriction 
alone: ghrelin levels increase in proportion to weight lost, while anorexigenic appetite 
modulator levels decrease or remain unchanged (Cummings, 2009; Koshy et al., 2013). 
These compensatory effects likely contribute to the high degree of weight regain with 
calorie restriction alone (Batterham and Cummings, 2016; Sumithran et al., 2011).  
 
Following RYGB, changes to appetite modulators support feelings of satiation to 
promote weight loss. The levels of anorexigenic appetite modulators, specifically CCK, 
GLP-1, and PYY, increase significantly after RYGB compared to both lean and matched 
(BMI, diabetes duration, age, sex) non-surgical controls who either had no intervention or 
equivalent diet-induced weight loss (Laferrère et al., 2008; Näslund et al., 1997). This 
effect is likely due to increased stimulation of enteroendocrine L-cells in the distal 
intestine following intestinal diversion, an effect in accordance with the hindgut 
hypothesis.  
 
Ninety percent of ghrelin is produced by the stomach and duodenum. Its levels have been 
reported as decreased due to reduced nutrient-stimulation following RYGB, an effect in 
accordance with the foregut hypothesis (Knop and Taylor, 2013; Koshy et al., 2013; 
Nguyen and Korner, 2014). Ghrelin also stimulates insulin counter-regulatory hormones, 
suppresses adiponectin (see Adipose Tissue – Adipokines section), blocks hepatic insulin 
signaling, and inhibits insulin secretion (Cummings, 2009; Pradhan et al., 2013). 
Therefore, decreased levels of ghrelin would not only suppress feelings of hunger, but 
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also improve insulin sensitivity, glucose metabolism, and promote anti-inflammatory 
adipokine profiles. 
 
However, changes in ghrelin levels following bariatric surgery have been inconsistent. 
Other studies of multiple methods of bariatric surgery show no consistent association 
with ghrelin levels, with some studies reporting an initial decrease in ghrelin followed by 
a rapid increase, whereas others note no changes (Pournaras and le Roux, 2010). While 
surgical technique variability may explain some of the disparities in reported 
postoperative ghrelin levels, the evidence that ghrelin levels definitively decreases is 
weak in the context of such heterogeneous results. Therefore, while the hindgut 
hypothesis appears to be consistent with changes in appetite modulators and incretins, the 
foregut hypothesis with regard to nutrient-stimulated ghrelin release and its role in 
affecting metabolic improvements and decreased appetite is unclear.  
Dopamine Receptors 
Dopaminergic receptors are distributed throughout the central and peripheral nervous 
system and are critically involved in a number of CNS functions, such as voluntary 
movement, feeding, mood, reward, sleep, attention, working memory and learning 
(Beaulieu and Gainetdinov, 2011). The primary reward pathway in the brain is the 
mesolimbic dopamine system, which controls individual responses to food, sex, and 
social interactions, and which mediates motivation and incentive drives. Consequently, it 
contributes to drug reward and addiction (Volkow et al., 2011).  
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The density of dopaminergic type 2 receptors in the mesolimbic brain areas is 
significantly decreased in severely obese patients, similar to that seen in the brains of 
drug-addicted patients (Volkow et al., 2011; Wang et al., 2001). This observation 
supports theories of food-addiction as a mechanism for obesity. Researchers postulate 
that a decrease in dopamine receptors would lead to greater sensitivity to endogenous 
dopamine production stimulated by food intake. This would lead to increased food 
craving. However, whether this is a cause of obesity or an effect in unknown (de Weijer 
et al., 2014).  
 
One study by Steele et al. (2010) observed an increase in the number of mesolimbic 
dopamine receptors following RYGB. Theoretically, this would reduce the sensitivity of 
dopamine receptors and the potency of dopamine signaling induced by food. However, 
this study used a small sample size and was contradicted by a later study which observed 
a RYGB-induced decrease in dopamine receptors (Dunn et al., 2010). Other studies have 
reported no significant changes in dopamine receptor availability at six week post-RYGB 
(de Weijer et al., 2014). Currently, there are no definitive conclusions with regard to 
changes in dopamine receptors following RYGB, nor the effects of these changes. More 
observational studies using larger patient populations are required to determine the effect 
of RYGB-induced changes to dopamine receptor number and sensitivity. Such changes 
may explain the reduced neural responsivity to food cues in the mesolimbic pathway and 
the shifts in food preference towards low-calorie foods, observed in both animal and 
human models (Barkholt et al., 2016; Ochner et al., 2011).  
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INCRETINS 
Incretins are hormones that stimulate insulin secretion in response to oral glucose, a 
phenomenon known as the “incretin effect” (Batterham and Cummings, 2016). Two of 
the most important incretins are GIP and GLP-1. One-half to two-thirds of postprandial 
insulin secretion are due to the actions of GIP and GLP-1, alone (Nguyen and Korner, 
2014). RYGB causes more rapid delivery of ingested food to the distal intestine where L-
cells are stimulated to release GLP-1, among other hormones (i.e. PYY, GLP-2). The 
increased nutrient-stimulated secretion of these incretins following RYGB and its 
beneficial effects on glucose homeostasis provide the foundation for the hind-gut 
hypothesis (Pok and Lee, 2014). The proximal intestine primarily secretes GIP from K-
cells and CCK from I cells. While a reduction in GIP and CCK would not support 
improvements in glucose homeostasis, researchers postulate that beyond the potential 
beneficial decreases in ghrelin, there may exist an “anti-incretin” secreted by the 
proximal intestine that would normally counter-balance the effects of incretins (Pok and 
Lee, 2014). However, as previously discussed (see The Debate section), the evidence in 
support of the foregut hypothesis is inconclusive and challenged.  
Glucagon-Like Peptide-1 
Glucagon-like peptide-1 (GLP-1) primarily mediates its actions directly through the 
GLP-1 receptor. GLP-1 has many functions affecting the brain, heart, liver, adipose tissue 
and stomach (Figure 7). In the pancreas, GLP-1 activates insulin secretion and 
biosynthesis, β-cell proliferation and neogenesis, inhibition of apoptosis, endoplasmic 
reticulum (ER) stress reduction, and restores glucose sensitivity in the β-cell via 
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upregulation of glucose transporters and glucokinases (Baggio and Drucker, 2007). The 
ability of GLP-1 to improve pancreatic function and ameliorate glucose homeostasis lead 
to the development of a number of GLP-1 agonists, such as Trulicity®, to treat diabetes 
(Diabetes.co.uk, 2017b).  
 
GLP-1 levels are substantially increased postprandially after RYGB, but not after other 
weight loss methods, such as LAGB or calorie restriction (Nguyen and Korner, 2014). 
Proof of concept models in rats using ileal interposition, a method to enhance L-cell 
nutrient and bile acid (BA) exposure without gastric restriction or malabsorption, 
Figure 7. GLP-1 Actions: Taken from Baggio and Drucker, 2007 
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demonstrate that rapid delivery of stomach contents to the distal intestine account for part 
of the higher GLP-1 levels (likely in addition to intestinal hyperplasia and hypertrophy 
induced by malabsorption – see Intestinal Adaptation Section) (Ramzy et al., 2014).  
 
In a minority of RYGB patients, severe postprandial hyperinsulinemic hypoglycemia 
emerges and is correlated to higher GLP-1 and insulin responses in these patients relative 
to asymptomatic RYGB patients. This demonstrates the potent, and potentially 
pathological, effects of GLP-1 (Goldfine et al., 2007). While short-term improvements in 
β-cell function and hepatic insulin sensitivity after IV glucose tests may be independent 
of elevated GLP-1 levels, diabetes remission three years postoperatively is observed only 
with oral, not IV glucose administration (Dutia et al., 2014). These results support the 
notion that while calorie-restriction may drive early benefits of RYGB, incretins and 
other gut-derived factors are important to long-term benefits.  
Gastric Inhibitory Polypeptide 
Gastric inhibitory polypeptide (GIP) primarily mediates its actions directly through the 
GIP receptor, a G-protein coupled receptor expressed in the pancreas as well as many 
extra-pancreatic tissues (Figure 8). In the pancreas, it shares many common effects with 
GLP-1, including enhanced insulin biosynthesis and secretion, stimulated β-cell 
proliferation and improved survival of β-cells. Disruption of GIP action via receptor 
antagonists or receptor gene disruption results in impaired oral glucose tolerance and 
defective glucose-stimulated insulin secretion in rodent models (Baggio and Drucker, 
2007).  
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In theory, given that the majority of GIP-secreting K-cells are located in the proximal 
intestine, RYGB would decrease postprandial GIP levels. However, while some studies 
report a decrease, others report no change or even an increase. These inconsistencies are 
likely due to methodological differences, particularly in surgical technique with regard to 
the sites of anastomoses (Nguyen and Korner, 2014). Despite the importance of GIP with 
normal gastrointestinal (GI) anatomy, its specific effects following RYGB appear to be of 
relatively less importance compared to the contributions of other incretins (i.e. GLP-1) 
and mechanisms.  
 
Figure 8. GIP Actions: Taken from Baggio and Drucker, 2007 
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Anti-Incretin 
The evidence for an “anti-incretin” molecule was first presented in a study by Rubino et 
al. (2006). Using a diabetic rat model, they performed a duodenojejunal bypass (DJB), a 
stomach-preserving RYGB that excludes the proximal intestine, or a gastrojejunostomy 
(GJ), a surgery that retained the proximal intestine’s connection to the stomach while 
adding a shortcut connecting the distal intestine to the stomach (Figure 9). In each 
treatment group, the rats were re-operated upon 
to either restore or exclude duodenal passage. 
Regardless of surgery order, exclusion of the 
duodenal passage via DJB significantly 
improved glucose tolerance, whereas restoration 
of the duodenal passage via GJ impaired 
glucose tolerance (Rubino et al., 2006). 
Currently, no human anti-incretin candidates 
exist, and this remains an important subject of 
investigation for both diabetes pathophysiology 
and therapeutic effects of bariatric surgery.  
 
  
Figure 9. Gastrojejunostomy (GJ): This 
operation creates an anastomosis between 
the jejunum and the stomach. The site of 
anastomosis at the jejunum is the same as 
in DJB, resulting in similarly rapid, early 
delivery of food from the stomach to the 
distal intestine. However, unlike the DJB, 
the GJ does not bypass the proximal 
intestine. Taken from Rubino et al., 2006.  
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INTESTINAL ADAPTATIONS 
Following RYGB, the small intestine undergoes a number of adaptations that improve 
metabolism. The alimentary limb, the portion of the distal intestine anastomosed to the 
small pouch stomach, undergoes hyperplasia and hypertrophy (Figure 10). Due to the 
proliferation of the intestinal cells generally, the number, but not the density, of incretin-
secreting (GLP-1 and GIP) cells increases, contributing to the “incretin effect” observed 
post-RYGB (See Incretins section). Moreover, Cavin et al. (2016) observed an increase 
in glucose utilization by intestinal cells to meet these enhanced metabolic demands under 
conditions of growth. Overexpression of basolateral glucose transporter-1 (GLUT1) and 
increased activity of the apical sodium-glucose linked transporter 1 (SGLT1) bring 
glucose into the intestinal cell from both the blood and the lumen, respectively. The 
increased alimentary and circulating glucose uptake and use by intestinal cells in the 
distal intestine, both during and between meals, prevents hyperglycemia and improves 
glycemic control, independent of insulin activity (Cavin et al., 2016).  
  
Figure 10. Hypertrophy and hyperplasia of crypt cells in the distal jejunum after RYGB: 
Left, hematoxylin-phloxine-saffron (HPS) stained section of the distal jejunum mucosa; Right, 
Ki67-immunostained (nuclear protein associated with cellular proliferation) of distal ileum. 
Perioperative, obese individual, no bariatric surgery. RYGB-operated, one year post-surgery. 
Taken from Cavin et al., 2016.   
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ADIPOSE TISSUE 
An obvious benefit of bariatric surgery is the decrease in total fat mass, with up to a 50% 
decrease within one-year of surgery (Galanakis et al., 2015). The mechanism of the 
benefits derived from this change relate to the relative distribution of adipose tissue, the 
size of individual adipocytes and their metabolic function. 
Distribution & Size 
There are two main compartments for fat: visceral adipose tissue (VAT), located in the 
peritoneal cavity and enveloping organs, such as the kidney and stomach; and 
subcutaneous adipose tissue (SAT), located under the skin (Frikke-Schmidt et al., 2016). 
Excess VAT is an independent risk factor for diabetes and CVD, demonstrating greater 
lipolytic capacity, hypertrophy, vascularization, and secretion of pro-inflammatory 
adipokines (Park et al., 2008; Sam et al., 2008). The increased SAT and VAT area is due 
to adipocyte hyperplasia and hypertrophy.  
 
The large diameter of hypertrophied adipocytes exceeds the diffusion distance of oxygen 
and causes cellular dysfunction and release of hypoxia-induced inflammatory compounds 
(see Adipose Tissue – Metabolic Function section). The primary outcome of this 
dysfunction is an increase in circulating free fatty acids (FFA). This occurs through a few 
mechanisms: hypertrophied adipocytes have 1) a reduced capacity to uptake and, thus, 
remove FFA from circulation, 2) an increased rate of lipolysis and release of FFA into 
circulation and lastly, 3) a decreased sensitivity to the effects of insulin (Frikke-Schmidt 
et al., 2016; Ibrahim, 2010). Normally, insulin both inhibits lipolysis and stimulates 
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lipogenesis. The loss of the former effect is pronounced and contributes to the flood of 
FFA into circulation (Frikke-Schmidt et al., 2016). 
 
The effects of raised levels of FFA, especially contributed by blood arriving from VAT 
circulation that empties directly into the portal vein, are inflicted strongly upon the liver. 
Peripheral insulin resistance causes the liver to be flooded with FFA, hepatic steatosis 
develops, and insulin resistance arises at the level of the liver as well as peripherally at 
the muscles. With the increase in FFA, the liver will increase TG synthesis and very-low-
density lipoprotein (VLDL) release into circulation. Human β-cells avidly take up FFA 
released by VLDL (White et al., 2016). The increase in TG stores in the β-cell, like in the 
adipocyte, causes cellular impairment, with a consequent decrease in glucose-stimulated 
insulin secretion. Resultant hyperglycemia compounds these metabolic dysfunctions and 
diabetes develops. These dysfunctions in the liver and pancreas as a key mechanism in 
the development of diabetes is called the “twin-cycle hypothesis” (Figure 11) (White et 
al., 2016).  
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Bariatric surgery corrects these effects through fat loss, especially a reduction in VAT 
area, and a decrease in adipocyte size to restore normal function and reduce peripheral 
and central insulin resistance (Aghamohammadzadeh et al., 2013; Cancello et al., 2013). 
With bariatric surgery, short-term fat loss occurs disproportionally in the SAT, whereas 
long-term fat loss occurs primarily in the VAT. VAT area loss is positively correlated to 
surgery-induced diabetes remission, independent of BMI and SAT area (Faria et al., 
2014). Decreases in adipocyte size has been strongly correlated to improved insulin 
sensitivity and diabetes remission (Andersson et al., 2014; Cotillard et al., 2014). 
Moreover, rapid weight loss following surgery confers benefits to high-density 
lipoprotein (HDL) levels and functionality. HDL is protective against apoptosis to β-cells 
Figure 11. Twin-Cycle Hypothesis: Taken from White et al., 2016.  
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and associated with RYGB-induced improvements in glucose homeostasis (Asztalos et 
al., 2010; Cernea and Dobreanu, 2013; Zvintzou et al., 2014).  
Adipokines 
Classically, white adipose tissue was viewed as an inert, storage molecule for FFA. 
However, recent discoveries have revealed that fat cells are important endocrine organs 
and mediators of innate immunity (Illán-Gómez et al., 2012; Kershaw and Flier, 2004). 
Adipokines classify all bioactive proteins released by adipocytes, many of which have 
been linked to adiposity. It is firmly established that obesity is associated with the 
appearance of a chronic low-inflammatory state, which may also mediate CVD and 
insulin resistance (Illán-Gómez et al., 2012; Monteiro et al., 2010; Xu et al., 2003).  Pro-
inflammatory adipokines, including C-reactive protein (CRP), interleukin-6 (IL-6) and 
tumor necrosis factor-alpha (TNF-α), directly contribute to this inflammatory state.  
 
Leptin is another important adipokine that signals satiation through the melanocortin 
anorexigenic pathway to suppress appetite (Oswal and Yeo, 2007). Its levels increase in 
obesity to reflect the amount of available fat stores. However, the chronic increase in 
leptin with obesity does not result in decreased appetite because a new set-point, or 
steady-steady level, is established as the body adapts to chronic over-nutrition. Leptin 
increases or decreases from this new set-point signal energy imbalances and stimulate 
feelings of satiation or hunger, respectively (Rosenbaum and Leibel, 2014). Higher 
overall levels of leptin, irrespective of set-point levels, stimulate pro-inflammatory 
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immune responses, contributing to the chronic inflammation profile of diabetes and 
obesity (Frikke-Schmidt et al., 2016).  
 
On the other hand, adiponectin is an anti-inflammatory adipokine, and is exclusively 
synthesized by adipocytes. Its synthesis is reduced in obesity. Adiponectin’s anti-
inflammatory properties include the production of anti-inflammatory mediators, such as 
interleukin-10 (IL-10) and interleukin-1 receptor agonist (IL-1RA) in inflammatory cells 
(Illán-Gómez et al., 2012).  
 
Following bariatric surgery, there is a dramatic shift from an inflammatory to an anti-
inflammatory adipokine profile. Illán-Gómez et al. (2012) measured adipokine levels in 
relation to anthropomorphic measures (i.e. BMI), insulin resistance and lipid parameters 
in 60 morbidly obese women, both before and up to a year after bariatric surgery. A year 
after surgery, they observed a significant, progressive increase in plasma adiponectin 
(p<0.001) and HDL (p<0.01), and a significant decrease in levels of IL-6 (p<0.001), low-
density lipoprotein (LDL; p<0.001), glucose (p<0.001), CRP (p<0.001), insulin 
(p<0.001) and HOMA-IR (homeostatic model assessment of insulin resistance; p<0.001; 
Table 2). Specifically, a post-operative association between IL-6 and CRP plasma 
concentrations with HOMA-IR suggest that these adipokines may serve as measures of 
chronic inflammation as a proxy for insulin resistance (Illán-Gómez et al., 2012). 
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A separate clinical study of post-operative bariatric surgery patients who underwent 
either RYGB or SG found that reduced rises in adiponectin levels characterized diabetes 
non-remission up to 2 years post-operatively, while changes in incretin levels were 
unrelated to remission status (Malin et al., 2014). This suggests the potential primacy of 
the role of adipokine effects over incretin effects in promoting diabetes remission.  Other 
factors significantly correlated with remission were pancreatic β-cell function and CRP 
levels (Figure 12) (Malin et al., 2014). These findings may provide valuable insight in 
predicting and preventing diabetes recurrence following bariatric surgery. 
 
 
Table 2. Anthropometrical, body composition and biochemical parameters of 
lean control and obese patients before and after bariatric surgery. 
 Lean Control  Baseline 12 months  
Age (years)  39.04 (8.91) 39.85 (10.39) 40.85 (10.39) 
BMI (kg/m2) 21.48 (1.77)** 47.65 (7.08) 30.50 (5.28)*** 
Fat Mass (kg) 14.45 (3.87)** 63.45 (15.52) 26.29 (10.78)*** 
Triglycerides 
(mmol/l) 
0.67 (0.27)** 1.65 (0.77) 0.91 (0.32)*** 
HDL (mmol/l) 2.01 (0.46)** 1.37 (0.25) 1.44 (0.28)** 
LDL (mmol/l) 2.61 (0.49)* 3.02 (0.72)  2.45 (0.54)** 
Glucose (mmol/l) 4.52 (0.41)** 6.61 (2.66)  4.73 (0.77)*** 
Insulin (pg/ml) 7.92 (5.24)** 19.92 (10.31) 6.22 (3.55)*** 
HOMA-IR  1.58 (1.07)** 6.24 *4.84) 1.36 (0.95)*** 
Adiponectin 
(μg/ml) 
16.68 (64.17)** 5.82 (2.93) 10.97 (5.56)** 
IL-6 0.92 (0.47)** 3.84 (1.67) 1.78 (1.66)** 
TNF-α 0.86 (0.67)** 2.10 (1.86) 2.11 (2.34) 
CRP (g/l) 1.71 (2.27)** 26.19 (23.17) 3.55 (2.86)** 
    
All data are presented as the mean (standard deviation). BMI, body mass index; 
HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high density 
lipoprotein; LDL, low density lipoprotein; FM, fat mass; IL-6, interleukin-6; TNF-α, 
tumor necrosis factor alpha; CRP, C-reactive protein. **p<0.01, ***p<0.001; p-
values are indicated for changes compared to baseline. Statistical analysis using 
Student’s t test. Adapted from Illán-Gómez et al., 2012. 
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Figure 12. Comparison of patients with and without diabetes remission at 12 and 24 months 
post-surgery: T2D, type 2 diabetes; DI, disposition index or β-cell function; CRP, C-reactive 
protein; TNF-α, tumor necrosis factor-alpha. (a) p <0.05; (b) p <0.01; (c) p <0.01; (d) p <0.05. 
Taken from Malin et al., 2014.  
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MICROBIOTA 
Gut microbiota, or gut flora, plays an active role in human health. Microbiota aid in 
digestion, can modify BA composition, and are an essential element of the innate 
immune system (Flint et al., 2012; Round and Mazmanian, 2009; Sekirov et al., 2010). 
However, gut microbiota imbalances can alter homeostasis, induce inflammation, and 
play an increasingly recognized role in obesity-related disorders, including diabetes 
(Musso et al., 2010; Sekirov et al., 2010). The development of diabetes from an altered 
gut microbiome acts through several mechanisms: increased absorption of dietary energy, 
altered fatty acid metabolism and composition in adipose tissue and liver, modulated 
incretin secretion, activated innate immune inflammation, and dysregulated intestinal 
barrier integrity by glucagon-like peptide-2 (GLP-2) (Musso et al., 2010).  
 
Agus et al. (2016) examined the effects of a “Western diet”, meals enriched in total fat 
and refined sugars, on microbiota composition and intestinal inflammation in a mouse 
model. They observed that “Western diet” causes an inflammatory environment, a 
decrease in species diversity and richness, and a change in microbial composition. In a 
shift from a “conventional diet” (higher in fiber, lower in total fat and refined sugars) to a 
“Western diet”, Proteobacteria levels decreased significantly while Firmicutes levels 
became more abundant (Agus et al., 2016). The importance of the relative levels of 
Firmicutes has been confirmed in human studies. Ley et al. (2006) found that the relative 
proportion of Bacteroidetes to Firmicutes, the two groups of dominant beneficial bacteria 
in the human gut, were tightly correlated with weight and weight loss. In obese 
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individuals, the ratio of Firmicutes:Bacteroidetes was large compared to lean controls, 
and this ratio decreased with weight loss on a low-calorie diet. 
 
Bariatric surgery induces similar changes in microbial composition from an obese to a 
lean microbiota profile (Aron-Wisnewsky et al., 2012; Furet et al., 2010; Zhang et al., 
2009). While one might argue that changes to gut-microbiota are due to calorie-
restriction associated with bariatric surgery and not the procedure itself, a number of 
observations support the role of bariatric surgery in inducing the change. In a study by 
Liou et al. (2013), germ-free mice were treated with fecal transplants from either RYGB-
treated mice or weight-matched sham-operated mice. Fecal transplants from RYGB-
treated mice caused weight loss, whereas the fecal transplants from the sham-operated 
mice caused weight gain (Liou et al., 2013). Moreover, changes in microbiota 
composition are most significant distal to the site of surgical manipulation in RYGB-
treated rat models, supporting the importance of the intestinal reconfiguration itself 
(Nguyen and Korner, 2014).  
 
Lastly, a human study by Tremaroli et al. (2015) examined differences in microbiota 
profiles related to bariatric surgery (RYGB or SG) and BMI. Bariatric surgery patients 
were BMI-matched to two groups of non-operated controls: those with the same pre-
surgical BMI (OB) and those with the same post-surgical BMI at the time of the study 
(Ob). There was a significant difference in microbiota profiles between the surgical 
patients and non-surgical controls. However, there was little within-in group difference in 
microbiota profiles among the surgical and non-surgical groups. Notably, the OB and Ob 
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shared similar profiles, despite differences in BMI. This finding provides compelling 
evidence that surgery-induced alterations to microbiota profiles are durable (lasting at 
least a decade) and independent of changes to BMI.  
 
Improvements to metabolism following surgery-induced changes to microbiota profiles 
may be mediated through changes to the BA-FXR-microbiome pathway (see Bile Acid 
Section). BAs and microbiota can affect one another. While BA pool size and 
composition can regulate the profile of gut-microbiota, microbiota, in turn, can 
deconjugate primary BAs or digest them to secondary BAs, increasing the total BA 
diversity (Liu et al., 2017; Nie et al., 2015). Microbiota have also been shown to 
influence the expression of hepatic enzymes required for BA biosynthesis (Sayin et al., 
2013). In summary, gut-microbiota regulate the biotransformation, biosynthesis, and 
transportation of BAs (Nie et al., 2015; Ridlon et al., 2006).  
 
Because of the large degree of cross-talk between BAs and microbiota, it is unclear if 
changes induced by bariatric surgery are primarily directed at microbiota or BA 
homeostasis. However, it is clear that changes to microbiota are durable and favorable for 
weight loss and diabetes remission.  
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BILE ACID 
Bile acid (BA) is synthesized in hepatocytes and is the end-product of cholesterol 
degradation, accounting for a major fraction of the daily cholesterol turnover in humans. 
Stimulated postprandially by cholecystokinin (CCK), the gall bladder contracts to release 
its contents. Biliary secretions of BA, cholesterol, phospholipids, toxic metabolites, and 
xenobiotics are important to maintain human health. BA, specifically, plays an important 
role in emulsifying dietary fats so that they can be absorbed (Chiang, 2013). The two 
primary BAs are cholic acid (CA) and chenodeoxycholic acid (CDCA), and they are 
often conjugated with glycine or taurine. The majority of BAs are reabsorbed in the ileum 
and recycled back to the liver via the portal vein. However, a small fraction of CA and 
CDCA are not reabsorbed and instead 
may be metabolized by gut-microbiota 
and converted to secondary BAs 
(Figure 13). Microbiota first 
deconjugate primary BAs and then 
bacterial 7α-dehydroxylase converts 
primary BAs to deoxycholic acid 
(DCA) and lithocholic acid (LCA). The 
majority of LCA is excreted into feces.  
BAs lost in feces are replenished by de 
novo synthesis in the liver to maintain a 
nearly constant BA pool (Chiang, 2013; Nie et al., 2015).  
Figure 13. Enterohepatic Bile Circulation: Taken 
from Liu et al., 2017 
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BAs self-regulate the size of the BA pool via the farnesoid-X receptor (FXR). BAs serve 
as endogenous ligands for the FXR. The most powerful ligand is CDCA, followed by, in 
order of affinity, LCA, DCA, and CA (Chiang, 2013; Staels and Fonseca, 2009). FXR, 
via FGF-19, suppresses the transcription of cytochrome P450 enzyme cholesterol 7α-
hydroxylase (CYP7A1), the enzyme that catalyzes the first and rate-limiting step of 
cholesterol’s conversion to primary BAs (Staels and Fonseca, 2009). Beyond BA 
homeostasis, FXR also plays an important role in lipid and glucose metabolism, 
downregulation of inflammation, and even expression of hepatic autophagy-related genes 
(Hollman et al., 2012; Nie et al., 2015). Via FGF-19,  FXR improves insulin independent 
glucose efflux and inhibits postprandial hepatic gluconeogenesis (Potthoff et al., 2011). 
FXR decreases the production of pro-inflammatory cytokines (IL-1β, IL-2, IL-6) and 
induces secretion of intestinal antimicrobials (Batterham and Cummings, 2016; 
Stojancevic et al., 2012).  
 
BAs also act through TGR5, a G-protein coupled receptor. Its most potent agonist is LCA 
and activation of the receptor directly stimulates L-cell secretion of GLP-1, GLP-2 and 
PYY (Batterham and Cummings, 2016; Pols et al., 2011). TGR5, like FXR, 
downregulates pro-inflammatory cytokines (Pols et al., 2011). Administration of both 
FXR and TGR5 agonists decrease hepatic steatosis, indicating the important role of these 
receptors’ actions in maintaining normal glucose homeostasis and insulin sensitivity 
(Chiang, 2013; Duboc et al., 2014).  
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A “Western” high-fat diet induces increased bile secretion. BAs, and especially 
secondary BAs, have strong antimicrobial properties. Therefore, only microbes tolerant 
to this will survive. These conditions promote the microbiota composition correlated with 
obesity and metabolic disorders: a higher ratio of Firmicutes:Bacteroidetes (Nie et al., 
2015; Yokota et al., 2012). To examine the effects of increased bile secretion with a high-
fat diet, Islam et al. (2011) fed rats one of three diets: a conventional diet, one moderate 
in CA (1.25mmol/kg), or one high in CA (5 mmol/kg). Their results confirm the 
microbial shifts to favor Firmicutes microbiota in the cecum (Figure 14). They also 
observed decreased serum adiponectin levels, an effect which would promote obesity-
related disorders (See Adipose Tissue Section) (Islam et al., 2011).  
 
Moreover, Firmicutes microbiota possesses 7α-dehydroxylation activity which converts 
primary BAs to secondary BAs, especially DCA and LCA (Gérard, 2013; Nie et al., 
2015). While CDCA is a strong FXR agonist, DCA, LCA, CA and their conjugates are 
Figure 14. Composition of cecal microbiota phyla of rats on various diets: Control, 
conventional diet. M-CA, diet supplemented with 1.25 mmol/kg of cholic acid. H-CA, diet 
supplemented with 5 mmol/kg of cholic acid. Data collected by sequencing of 16S rRNA gene 
clone libraries. Mean percentage (%) of the total microbiota population shown. Each diet had n=6 
rats. “Unclassified” microbiota were not listed in the Ribosomal Database. Taken from Islam et al., 
2011.  
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very weak agonist in such a way that they act as partial antagonists by interfering with 
CDCA’s ability to bind FXR (Modica et al., 2010; Tomkin and Owens, 2016). Therefore, 
the increase in secondary BAs, which is correlated with obesity and diabetes, may inhibit 
protective effects of FXR against insulin resistance and hyperglycemia (Prawitt et al., 
2011).  
 
RYGB is associated with increases in BAs, FGF19, GLP-1 and PYY (Batterham and 
Cummings, 2016). However, as previously discussed, it is the relative proportions of 
primary and secondary BAs, not an absolute increase in total BAs, that is significant to 
BA-induced downstream signaling. A study by Kohli et al. (2013a) found that an increase 
in total circulating BAs alone was not a significant predictor of changes in glucose 
homeostasis or energy metabolism. Instead, Kohli et al. (2013a) reported that increased 
TGR5 signaling was correlated with increased GLP-1, a contributor to glucose 
metabolism benefits. The increase in FGF19 levels is indicative of increased FXR 
signaling (Jansen et al., 2011). Increases in FGF19 levels do not occur with medical 
management of diabetes or LAGB (Pournaras et al., 2012; Sachdev et al., 2016). The 
importance of FGF19 and FXR signaling to metabolic improvements achieved by RYGB 
is underscored by the correlation between high FGF19 levels and sustained diabetes 
remission following RYGB (Table 3) (Gerhard et al., 2013).  
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Researchers postulate that the mechanism for bile-related improvements following 
RYGB relates to the altered anatomy of the GI tract, resulting in both more rapid delivery 
of BAs to the terminal ileum and delayed mixing of BAs with ingested food (Pournaras et 
al., 2012). This theory is supported by bile diversion procedures in obese rat models. 
Following bile diversion, in which a catheter is placed in the common bile duct and 
anchored at the other end to the mid-distal jejunum for 4-5 weeks (simulating intestinal 
reconfiguration in gastric bypass), rats lost significantly more weight, had improved 
glucose tolerance, higher post-prandial GLP-1 levels, and reduced hepatic steatosis and 
ER stress (Figure 15) (Kohli et al., 2013b). Changes in bile circulation certainly 
Table 3. FGF19 level change from pre- to post-RYGB 
between three groups 
Group (sample 
size) 
Percent of patients 
with increase (%) 
Median FGF19 Change 
from pre- to post-RYGB 
in pg/ml (IQR) 
No-D (37) 68 44.5 (-14.6 to 117.8)** 
D-R (45) 76 101.5 (7.5 - 168.3)*** 
D-NoR (30) 77 86.2 (2.1 - 200.8)** 
No-D, patients without diabetes; D-R, patients with diabetes 
remission for at least 12 months after surgery; D-NoR, patients 
without diabetes remission at any time after surgery. There were 
no significant differences between groups with regard to the 
magnitude of change from pre- to post-RYGB. There were no 
significant differences between groups (Kruskal-Wallis test). All 
p-values reflect within groups difference (evaluated using the 
Wilcoxon signed-rank test) **p <0.01, ***p <0.001. Adapted 
from Gerhard et al. 2013. 
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contribute to part of the beneficial effects of RYGB, and BA receptors represent new 
potential therapeutic targets.  
Figure 15. Anthropomorphic and biochemical changes in rats following bile diversion: Top left, 
graphical representation of bile diversion, note the proximal intestine remains intact. Top right, body 
weight (g) after surgery (repeated measures ANOVA: *, p < .05 BD vs SH). Bottom left, fasting insulin 
levels (ng/ml) at 4 weeks post-surgery, with decreased levels representing improved insulin sensitivity 
(ANOVA, post hoc Tukey's; *, p < .05 SH vs BD; **, p < .01 Naïve vs BD). Bottom right, postprandial 
(15 min) GLP-1 levels (pg/ml; ANOVA, post hoc Tukey's: *, p < .05 for BD-15 and BD-30 vs SH). 
Naïve: obese, non-surgical control rats. Sham: obese rats who underwent a sham surgery. BD: obese 
rats who underwent bile diversion surgery. BD-15, BD-30, 15 and 30 days after bile diversion, 
respectively. Adapted from Kohli et al., 2013b.   
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PSYCHOSOCIAL & BEHAVIORAL CHANGES 
Important, yet often overlooked benefits of bariatric surgery are those to self-perception 
and quality of life. Obese people often experience social stigma and shaming, as well as 
discrimination by health care providers. Living with obesity presents challenges 
completing day-to-day activities, managing additional costs (i.e. healthcare, personal 
assistance, custom-made clothing and devices), coping with social exclusion, and even 
sleeping (Uzogara, 2017).  
 
A study by Choban et al. (1999) assessed patients’ quality of life before RYGB and at 
interim points afterward (3 to 12 months and at their weight plateau after more than 18 
months). Using the Short-Form 36 (SF-36)5 prior to surgery, patients with clinically 
severe obesity scored significantly lower than the general population in all areas except 
daily challenges due to emotional problems. After RYGB, at the plateau period, patients 
SF-36 scores improved in all areas and were the same, or significantly better, than scores 
of the national “normal weight” population (Choban et al., 1999).  
 
Improvements to self-perception and mental health, enhanced social interaction, and 
perception of fewer limitations in daily life may support healthy life-style behaviors, such 
as physical fitness and diet. They may also reduce unhealthy behaviors, such as drinking 
                                                        
5 The SF-36 is a patient-response survey that assesses eight health concerns: physical functioning, bodily 
pain, role limitations due to physical health problems, role limitations due to personal or emotional 
problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. (RAND 
Corporation, 2017).  
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and binge-eating, which may otherwise jeopardize metabolic benefits derived from 
bariatric surgery (Koshy et al., 2013).  
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CLINICAL IMPLICATIONS 
Risks of Bariatric Surgery 
The physiological and metabolic changes following bariatric surgery are significant. 
While it provides enormous benefits to patients, it is a major surgery and carries some 
risk.  
 
Laparoscopic techniques are less invasive and associated with fewer peri- and 
postoperative complications. Open RYGB surgeries carry a higher risk of complication 
than the standard laparoscopic technique. The conversion rate from laparoscopic to open 
surgery is low. A clinical review of 1160 cases of laparoscopic RYGB surgery had only 
three cases (1.6%) that were required to convert to an open procedure due to severe 
adhesions (Schauer et al., 2000). The conversion rate may be as high as 8% among less 
experienced surgeons (Brethauer et al., 2006). Clinical outcome data from the Bariatric 
Longitudinal Database, including 81,751 RYGB patients, reports a 0.15% mortality rate 
(Benotti et al., 2014). For reference, this is less than the 0.30 – 0.65% mortality 
associated with common hip replacement surgery (Berstock et al., 2014). Overall, the risk 
of short-term major complications is 10-15%, but has been reported as low as 3.35%, 
while late complication risk ranges from 5-10%6 (Kashyap et al., 2010; Schauer et al., 
2000).  
 
                                                        
6 See Table 4 for a list of potential complications.  
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The most common type of long-term complication following RYGB is nutritional 
deficiency. While close provider follow-up and vitamin supplementation may help 
prevent deficiencies, these occur in 30-70% of patients (Kashyap et al., 2010). The most 
common types include vitamin B12, folate, zinc, iron, copper, calcium, and vitamin D 
deficiency and can lead to secondary problems such as osteoporosis, hematological 
disorders, and in extreme cases, death (Chen et al., 2013; John and Hoegerl, 2009; Wade 
et al., 2010). 
Table 4. Potential Bariatric Surgery Complications 
 
 
Hemorrhage  
Deep Vein Thrombus 
Diarrhea/constipation 
Bowel obstruction 
Candy Cane Syndrome 
(pain in non-functioning 
bowel requiring resection)  
Peritonitis  
Dumping Syndrome 
(nausea, diarrhea, bloating, 
fainting, anxiety) 
 
 
Dehydration  
Nutritional deficiencies  
Gallstones  
Kidney Stones  
Acid Reflux  
Hyperinsulinemia 
Hypoglycemia  
Incisional hernia  
Marginal Ulcer  
Surgical Wound infection 
 
 
The risk of complications is very low and good 
postoperative care, follow-up and practices can minimize 
risk. Most complications may be completely resolved with 
treatment. Source: Rovito, 2017 
 
Though there are risks, the benefits appear to outweigh them. The metabolic changes 
achieved by RYGB, as previously discussed, drastically improve health and quality of 
life. Patients who undergo RYGB have a significantly reduced long-term mortality risk 
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compared to matched controls (Adams et al., 2007; Craig et al., 2016). Adams et al. 
(2007) found a 40% decreased risk of mortality among the RYGB group compared to 
non-surgical controls (Figure 16). A notable contributor to this effect was the 92% 
decrease in diabetes-specific mortality, the largest reported disease-specific mortality 
decrease. There is strong evidence to support RYGB as a standard treatment for obesity-
related diabetes.  
Figure 16. Long-term survival according to BMI in the RYGB group and non-surgical control 
group: survival data was computed using one-to-one matching based on sex, BMI (presurgical 
measurement in the surgery group and self-reported BMI at the time of license application, corrected 
for self-reporting bias), age and year (of surgery or license application). BMI, Body Mass Index. 
Taken from Adams et al., 2007. 
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Improved Indications for Bariatric Surgery as a Diabetes Treatment 
Currently, the indications for bariatric surgery as a treatment option for diabetes are 
largely limited to BMI, diabetes medical management status, and obesity-related co-
morbidities, such as hypertension, sleep apnea, and non-alcoholic fatty liver disease, to 
name a few. However, these indicators reveal little with regard to the probability of 
successful diabetes remission following such an extreme, albeit often effective procedure. 
Long-term diabetes recurrence and weight gain following bariatric surgery are not 
uncommon. In a five-year prospective study examining surgical failure of RYGB, 
characterized by less than 50% of initial excess weight lost, failure rates ranged from 8% 
to nearly 20% of patients (Magro et al., 2008). Diabetes recurrence rates following 
RYGB range between 20% to nearly 60% based on HbA1c levels and re-initiation of 
diabetes medication (Buchwald et al., 2004; Knop and Taylor, 2013; Pournaras et al., 
2012). 
 
A crucial point is that bariatric surgery cannot salvage end-stage β-cell failure, and while 
these patients may experience a temporary improvement in glucose homeostasis, they 
will eventually relapse and require insulin treatment. In one study, approximately 20% of 
diabetic patients treated with RYGB to achieve diabetes remission had relapsed between 
3 to 5 years post-surgery. The duration of diabetes prior to surgery emerged as an 
important factor to explain this result. Compared to patients with a shorter history of 
diabetes, those with more than a five-year history of diabetes prior to surgery were 3.8 
times more likely to have diabetes recurrence (Koshy et al., 2013; Ramos, 2012).  
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Length of diabetes duration prior to surgery is a proxy for irreversible β-cell failure. 
Other proxies for β-cell failure include insulin usage and C-peptide levels (a by-product 
of endogenous insulin production) (Batterham and Cummings, 2016; Cernea and 
Dobreanu, 2013). The hyperglycemic clamp technique is the gold-standard measurement 
of β-cell function by measuring first- and second-phase insulin secretion. However, this 
technique is complex, costly, and time-consuming, limiting its clinical applicability. 
Therefore, other proxies are an acceptable means of evaluation. Futures studies should 
seek to identify threshold levels to determine irreversible β-cell failure, which, in turn, 
could serve as a useful indicator for bariatric surgery as a diabetes treatment. 
  
Personalized, also known as precision, medicine is a growing field. According to a 2016 
report from the Personalized Medicine Coalition, personalized medicines have accounted 
for more than 20% of all drugs approved by the U.S. Food and Drug Administration 
(FDA) for the third year in a row (Personalized Medicine Coalition, 2017a). The basis for 
personalized medicine lies in the discrepancies between outcomes and reactions to 
different drugs and procedures across patients, especially with regard to cancer 
chemotherapy. Using diagnostic genetic markers derived from genome-wide association 
studies (GWAS), as well as patient history, circumstances and values, health care 
providers are able to tailor treatments to achieve better results (Personalized Medicine 
Coalition, 2017b).  
 
GWAS have revealed single nucleotide polymorphism (SNP) markers and profiles that 
may allow providers to predict weight loss following bariatric surgery. Still et al. (2011) 
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stratified patients by BMI (greater or less than 50kg/m2) and genotypes based on the total 
number of FTO, INSIG2, MC4R, and/or PCSK1 obesity-associated gene alleles with SNP 
markers (0-8 alleles)7. They conducted an association analysis between these variables 
and the percentage of excess body weight lost following RYGB over a 30-month period. 
Initial BMI had a significant impact on weight loss trajectory (P<0.0001). Patients with a 
BMI greater than 50kg/m2 experienced slower and less pronounced weight loss compared 
to those under 50kg/m2, with no significant difference observed between SNP profiles. 
On the other hand, among patients with a BMI of less than 50kg/m2, an allelic dosage 
effect was present with weight loss, with fewer obesity-linked alleles associated with 
greater weight loss (P<0.001) (Figure 17).  
 
One gene is particular, MC4R, encodes the melanocortin receptor and plays a central role 
in energy homeostasis and somatic growth (Weizmann Institute of Science, 2017a). 
Mutations in the MC4R gene resulting in only a single functional copy are the most 
common type of mutation associated with monogenetic obesity (Nguyen and Korner, 
2014). Mirshahi et al. (2011) sequenced for genetic variants of the MC4R alleles to 
examine their effects on weight loss and diabetic status. They found that the I251L and 
V103I variants were both negatively associated with obesity. Patients with the I251L 
allele, in particular, experienced dramatically faster, greater, and more persistent weight 
loss compared to non-carriers, as well as lower HOMA-IR values. The importance of 
MC4R to weight loss was also observed in an animal model in which MC4R null mice 
                                                        
7 See Appendix B on genes associated with obesity 
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lost significantly less weight following RYGB than mice heterozygous for the MC4R 
(Hatoum et al., 2012).  
 
 
While many changes and improvements in glycemia are independent of weight loss, 
these studies provide a foundation upon which to collect evidence of genetic markers and 
outcomes for a diabetes-specific population. Analogous to pharmacogenomics in 
personalized medicine, using GWAS to predict surgical phenotype and outcome give rise 
Figure 17. Plot of linear mixed regression model of percentage initial excess body weight vs. time 
post-RYGB by obesity SNP alleles and threshold BMI: Colored bands are 95% confidence intervals 
for weight loss curves. Continuous lines are for BMI <50, dashed lines are for BMI >50. For obesity-
associated SNPs: yellow, 0 alleles; green, 1-2 alleles; blue, 3-4 alleles; red, 5+ alleles. .  Taken from 
Still et al., 2011. 
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to the same opportunities to tailor surgical indications and methods. For instance, given 
the limited weight loss following RYGB observed in patients with a BMI over 50kg/m2, a 
more aggressive technique, such as BPD, and longer postoperative clinical follow-up 
may be recommended. Similarly, patients with a lower BMI and fewer obesity-associated 
alleles may achieve similar benefits with a less invasive procedure, such as LAGB (Still 
et al., 2011). Moreover, a greater understanding of the genes responsible for the success 
or failure of bariatric surgery and their corresponding function may help elucidate the 
mechanisms chiefly responsible for surgery-induced improvements in glucose 
homeostasis. These discoveries, in turn, could lead to targeted drug therapies as a non-
surgical alternative.  
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CONCLUSION 
Bariatric surgery, especially RYGB, provides significant metabolic improvements. The 
mechanism for these improvements takes many forms. While calorie restriction alone 
may induce short-term beneficial reductions in fat and epigenetic changes that improve 
pancreatic function, its success is ultimately limited by compensatory mechanisms in the 
long term (i.e. elevated ghrelin, decreased GLP-1). The hindgut hypothesis may describe 
the over-arching mechanism that triggers a cascade of long-term metabolic benefits 
through BA circulation, incretins, appetite modulators, intestinal adaptations and 
microbiota changes. Improvement to the pro-inflammatory state associated with obesity 
and diabetes seems to be mostly mediated by changes to adipokine secretions and the 
interactions between BAs and microbiota. 
  
Bariatric surgery can provide the enormous benefit of inducing diabetes remission. 
Through this review, it emerged that factors such as BMI decreases and SAT area loss are 
not correlated to diabetes remission. While bariatric surgery cannot rescue terminal β-cell 
failure, a number of surgery induced-metabolic changes can help restore β-cell function, 
glucose homeostasis, and insulin sensitivity. Changes correlated with diabetes remission 
include VAT area loss, decreases in adipocyte size and CRP levels, and increases in 
adiponectin and FGF19 levels. The association of increased incretin levels, specifically 
GLP-1, with diabetes remission is unclear. GLP-1 levels may have a greater effect over 
time. One study of diabetes remission after two years indicated no correlation with GLP-
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1 levels (Dutia et al., 2014). Meanwhile, another study reported a correlation at three 
years post-operatively (Malin et al., 2014).  
 
While the hindgut hypothesis may be responsible for long-term metabolic benefits, it 
appears that induced changes beyond the traditional incretin effect have a more 
significant impact, such as bile circulation. With regard to the foregut hypothesis, there is 
no conclusive evidence of a duodenal factor that would have anti-incretin effects, or 
otherwise. It seems more likely that duodenal bypass supports calorie restriction and 
weight loss through additional malabsorption that contributes to early metabolic benefits.  
 
To return to the debate of weight loss/calorie restriction versus hindgut/foregut 
hypotheses, the latter of which emphasize the primacy of intestinal reconfiguration, all 
observations are challenged by a question of cause and effect. Is weight loss the cause of 
improvements in insulin sensitivity and glucose homeostasis? Or are other 
enteroendocrine changes and adaptations which result in improved metabolism the cause 
of weight loss? While some studies find correlations between weight loss and diabetes 
remission, others observe changes before significant weight loss and with no long-term 
correlation between BMI and diabetes remission. There may be no clear-cut order of 
cause and effect. Instead, the link between weight loss and enteroendocrine changes with 
regard to surgery-induced metabolic improvements may be synergistic, a positive 
feedback loop.  
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While this review attempted to provide a comprehensive picture of the potential 
mechanisms responsible for surgery-induced metabolic improvements and diabetes 
remission, this is an enormous field of inquiry. A growing area of research not addressed 
in this review relates to central nervous system changes and signaling patterns, especially 
with regard to insulin-independent gut-brain-liver neural axis and neural activity changes 
in response to food cues (Beraza and Trautwein, 2008; Ochner et al., 2011; Scarlett and 
Schwartz, 2015). Future research addressing these mechanisms and other changes 
following bariatric surgery will further our understanding of the pathophysiology of 
obesity and diabetes, and advance therapeutic development.  
 
Precision medicine may help improve outcomes with more selective and informed choice 
of surgical method and degree of post-operative follow-up and support. Not only can 
indications be improved, but current practices can also evolve to align more with well-
established indications. The Longitudinal Assessment of Bariatric Surgery Consortium 
(2009) published a report of 4476 patients who underwent bariatric surgery, and who 
collectively had a median BMI of 46.5 kg/m2 (46.5 kg/m2 for RYGB). This median BMI 
is high considering that the American Society of Metabolic and Bariatric Surgery 
recommends surgery for people with a BMI of 35 or 40 kg/m2, with or without diabetes 
(ASMBS, 2017a). A higher initial BMI not only carries a greater risk of complications, 
but is also dramatically correlated with reduced weight loss benefits at an initial BMI of 
greater than 50 kg/m2 (Still et al., 2011). This disparity between policy and practice 
represents an opportunity to become more proactive in care.  
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Despite the well-established benefits of bariatric surgery, an estimated less than 1% of 
candidates worldwide undergo surgery (Westerveld and Yang, 2016). There are a number 
of reasons for this statistic, including patient and physician perceptions and attitudes, 
patient-physician interaction, lack of resources, and cost burden (Westerveld and Yang, 
2016). In countries where healthcare resources are available, such as the United States 
and Canada, the main barriers to bariatric surgery are not costs and insurance coverage, 
but rather patient and provider misinformation with regard to the risks of bariatric surgery 
and a false perception of financial barriers (Afonso et al., 2010; Wharton et al., 2016). 
Though diabetes and obesity is virtually a pandemic, the barriers to bariatric surgery are 
even more pronounced in countries lacking the same depth of financial resources and 
expertise available in the United States. Thus, research that informs the mechanisms 
responsible for the metabolic improvements induced by surgery is crucial to develop new 
drug targets and therapies that may be more accessible to people around the world.  
 
Until new therapies are developed, bariatric surgery, especially RYGB, is a good 
treatment option for clinically obese diabetics. Prolonged diabetes remission rates 
following RYGB are excellent. Even in the event that one does not technically achieve 
diabetes remission, or has diabetes recurrence, it is important to remember that 
hyperglycemia and insulin resistance exist on a continuum. Literature that reports on 
diabetes remission may fail to emphasize the overall metabolic and psychological 
benefits to patients that do not achieve this threshold. Therefore, this thesis supports the 
new indications by the 2nd Diabetes Surgical Summit for proactive bariatric surgery 
treatment of diabetes at lower BMIs.  
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Despite all the evidence, the patient’s choice to undergo bariatric surgery is a momentous 
one: it comes with a life-long commitment to lifestyle changes, diet, vitamin 
supplementation, and physician follow-up. However, bariatric surgery achieves what diet 
and lifestyle changes alone cannot: rapid and profound improvements to metabolism, 
including increased incretin levels and altered bile circulation, microbiota profile, neural 
responsivity to food cues and appetite modulator levels that oppose typical compensatory 
responses to restrictive diet. Thus, bariatric surgery is perhaps the most successful option 
for obese diabetics hoping to achieve a healthier, longer life.  
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APPENDIX A: BARIATRIC SURGERY METHODS 
Information and figures taken from American Society for Metabolic and Bariatric 
Surgery (2017b). 
Laparoscopic Adjustable Gastric Banding (LAGB): 
An adjustable band is placed around the top of the 
stomach in order to create a small pouch, a restrictive 
measure. The stomach is reduced in size gradually 
over time with repeated adjustments by filling the band 
with sterile saline injected through a port placed under 
the skin. There are no malabsorptive measures with 
this procedure. While it is a reversible, adjustable 
procedure and has the lowest risk of postoperative 
complications and nutritional deficiencies, it is less successful in achieving weight loss 
and has the highest rate of re-operation. Moreover, it 
requires a foreign object remain in the body, which 
can possibly slip from position or, in rare cases, erode 
into the stomach.  
 
Sleeve Gastrectomy (SG):  
This procedure reduces the size of the stomach by 
approximately 80%, to the point at which it resembles 
a tube or sleeve. The smaller stomach is a restrictive 
Figure A1. Laparoscopic 
Adjustable Gastric Banding  
Figure A2. Sleeve Gastrectomy  
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measure. The decrease in ghrelin levels from the reduced stomach also contributes 
significantly to reducing feelings of hunger and promoting glycemic control. It is a less 
technically complex procedure: it does not require any foreign objects, as in LAGB, or 
bypass/re-routing of food, as in RYGB. Like RYGB, there is a risk of long-term vitamin 
deficiencies. It is also an irreversible procedure. 
 
Roux-en-Y Gastric Bypass (RYGB): 
The stomach is split into a small pouch adjacent to 
the esophagus, while the intestine is split to create a 
proximal biliopancreatic limb and a distal Roux 
limb. The Roux limb is anastomosed to the small 
pouch stomach. The bottom of the biliopancreatic 
limb is anastomosed to the distal Roux limb. In this 
way, stomach acids and digestive enzymes mix 
with food after it has passed through a long part of 
the Roux limb.  
 
The smaller stomach is a restrictive measure, while 
the bypassed stomach and proximal intestine is a 
malabsorptive measure. This method has excellent results with regard to weight loss and 
diabetes remission. However, it is more complex than either the LAGB or SG, potentially 
Figure A3. Roux-en-Y Gastric 
Bypass  
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has a higher risk of complications and nutrient deficiencies, and requires more extreme 
lifestyle and diet changes, and clinician follow-up.   
 
Biliopancreatic Diversion (BPD):  
 
A small, tubular stomach pouch is created by 
removing a larger part of the stomach. The duodenum 
is then divided just past the outlet of the stomach and 
roughly three-quarters of the way down the small 
intestine. The proximal intestine, which remains 
connected to the pancreas and gall bladder, is 
reconnected to the distal small intestine.  
 
This procedure uses restrictive methods very similar 
to SG and malabsorptive methods similar to RYGB. It differs from RYGB in that a large 
portion of the stomach is irreversibly removed, a greater portion of the proximal intestine 
is bypassed, and bile and pancreatic secretions do not mix with stomach acid and food 
until much further in the GI tract. This procedure shares many of the same benefits as 
RYGB, but they are more pronounced in BPD. It is the most effective method in treating 
diabetes. However, it has the highest complication rate, a greater risk of nutritional 
deficiencies, and requires intensive follow-up and strict adherence to dietary and lifestyle 
changes.  
  
Figure A4. Biliopancreatic 
Diversion  
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APPENDIX B: GENES ASSOCIATED WITH OBESITY 
Information and figures taken from GeneCards®: The Human Gene Database (2017b).  
Fat Mass and Obesity-Associated (FTO) gene: 
This was first gene locus associated with adiposity (Fawcett and Barroso, 2010). It 
encodes a dioxygenase that repairs single-stranded RNA and DNA containing 3-
methyuracil or 3-methyluracil, respectively. It also specifically demethylates N(6)-
methyladenosine RNA, which is most common internal modification of messenger RNA 
(mRNA) in higher eukaryotes. This function contributes to the regulation of global 
metabolic rate, thermogenesis, adipocyte differentiation (to brown or white adipocytes), 
and energy homeostasis. SNPs in this gene are strongly associated with BMI, obesity and 
type II diabetes.  
 
Insulin-induced Gene 2 (INSIG2):  
This gene encodes an ER protein that mediates feedback control on cholesterol synthesis 
by binding sterol regulatory element binding proteins (SREBPs), transcription factors, so 
that they cannot be activated by SREBP cleavage-activating protein, in the presence of 
low sterol levels. Activated SREBPs upregulate synthesis of sterols. 
Figure B1. FTO gene position: Located on chromosome 16q at position 12.2 
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Melanocortin 4 Receptor (MC4R):  
This gene encodes a G-protein-coupled cell-surface receptor, bound by 
adrenocorticotropic and melanocyte-stimulating hormone. It is important in downstream 
signaling of anorexigenic and orexigenic appetite modulators. Defects in the gene are a 
cause of autosomal dominant obesity.  
 
Proprotein Convertase Subtilisin/Kexin Type I (PCSK1):  
This gene encodes a protease, one of seven that specifically cleaves a basic amino acid at 
single or paired basic residues. It functions mostly in the neuroendocrine system and 
brain. Defects in this gene are associated with diabetes and related to incretin synthesis, 
secretion and inactivation.   
Figure B2. INSIG2 gene position: Located on chromosome 2q at position 14.1.  
Figure B3. MC4R gene position: Located on chromosome 18q at position 21.3 
Figure B4. PCSK1 gene position: Located on chromosome 5q at position 15.0 
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